CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Explore options for retirement accounts at 50. Make informed choices to secure your financial future.
24,046 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
AI momentum has shifted, and Cerebras stock's volatility comes into sharper focus for investors. This guide breaks do...
Axcelis Technologies has seen its stock surge this year, riding AI-chip demand. This guide breaks down what the compa...
A nationwide recall affects roughly 13,514 Amana Window-Room and Through-the-Wall air conditioners, plus a handful so...
A Brixton bank branch faced a bold scam when a man wore an old G4S uniform to obtain cash. This is how the asked cash...
Tech-focused investors watched TeraWulf surge after a major AI data-center lease deal, signaling potential recurring ...
A surprising slide in Micron shares has investors weighing memory cycles, AI demand, and competitive pressure. This g...
When penguin stock popped today, investors asked: what changed in a single session? This article breaks down the cata...
Rivian just raised its vehicle guidance to 70,000 units while a company director sold shares. This article breaks dow...
Stock splits grab headlines, but the real question for investors is whether the move changes the investment case. Thi...
IBM recently released a preliminary quarter that underscored a broader pattern: AI budgets are shifting. This article...
When a founder sells a sizable stake, investors take note. This article digs into the implications of airbnb co-found...